Home › Depression › NCT02568878
Creatine for Depressed Male and Female Methamphetamine Users
RecruitingPhase 3
An Open-Label Pilot Study of Creatine for Depressed Male and Female Methamphetamine Users
Who can join
Ages 18 to 59 · All sexes
Full eligibility criteria
Inclusion Criteria: * Current primary diagnosis of methamphetamine dependence or abuse, with methamphetamine preferred drug of abuse * Current diagnosis of major depressive disorder (primary or substance-induced) * Current diagnosis of an anxiety disorder (primary or substance-induced) * Current Hamilton Depression Rating scale score \> or = to 16 * Current Hamilton Anxiety Scale score \> = to 18 * If taking a psychotropic medication for depressed or anxious mood, regimen must be stable for \> = to 4 weeks prior to creatine treatment initiation Exclusion Criteria: * Persons unable to provide adequate informed consent * Persons who are at clinically significant suicidal or homicidal risk * Primary substance-related diagnosis other than methamphetamine dependence or abuse * Positive pregnancy test (females only) * History of renal disease * Clinically significant medical or neurological illness identified by history, physical exam and laboratory testing * History of hypersensitivity reaction to creatine
About the study
* Assess the antidepressant/anxiolytic effect of creatine in male and female methamphetamine users * Assess creatine's effect on methamphetamine use * Assess the safety of creatine in male methamphetamine users with depression
What is being tested
- Creatine monohydrate (drug)
Sponsor: Montana State University · Participants: 29 · Started: 2015-11
Contact the study team
- Tracy Hellem, PhD · Phone: 406 243 2110
Official record on ClinicalTrials.gov — NCT02568878
Locations in the U.S.
| Montana | Montana State University College of Nursing (Missoula campus), Missoula |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.